 Thomas Morrison
Concepts (472)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chikungunya virus | 30 | 2024 | 61 | 11.100 |
Why?
| | Chikungunya Fever | 27 | 2024 | 61 | 9.110 |
Why?
| | Alphavirus Infections | 28 | 2022 | 41 | 8.850 |
Why?
| | Ross River virus | 18 | 2021 | 22 | 4.710 |
Why?
| | Viral Envelope Proteins | 11 | 2022 | 74 | 2.690 |
Why?
| | Interferon Type I | 9 | 2021 | 129 | 2.180 |
Why?
| | Host-Pathogen Interactions | 9 | 2021 | 296 | 2.150 |
Why?
| | Alphavirus | 9 | 2022 | 17 | 1.950 |
Why?
| | Virus Replication | 22 | 2022 | 396 | 1.780 |
Why?
| | Virulence Factors | 5 | 2018 | 139 | 1.580 |
Why?
| | Receptors, Immunologic | 3 | 2023 | 203 | 1.550 |
Why?
| | Lymph Nodes | 4 | 2024 | 423 | 1.510 |
Why?
| | Disease Models, Animal | 23 | 2022 | 3587 | 1.480 |
Why?
| | Antibodies, Viral | 15 | 2022 | 527 | 1.430 |
Why?
| | Animals | 83 | 2024 | 32162 | 1.380 |
Why?
| | Adaptive Immunity | 5 | 2020 | 157 | 1.340 |
Why?
| | Mice | 48 | 2023 | 15087 | 1.330 |
Why?
| | Viral Proteins | 12 | 2019 | 286 | 1.330 |
Why?
| | Viral Load | 11 | 2021 | 406 | 1.260 |
Why?
| | Newcastle disease virus | 13 | 2001 | 17 | 1.230 |
Why?
| | Antiviral Agents | 8 | 2021 | 651 | 1.220 |
Why?
| | Viruses | 4 | 2022 | 94 | 1.200 |
Why?
| | Mice, Inbred C57BL | 26 | 2021 | 4780 | 1.190 |
Why?
| | Encephalitis Virus, Venezuelan Equine | 4 | 2021 | 4 | 1.180 |
Why?
| | Viral Vaccines | 4 | 2022 | 90 | 1.180 |
Why?
| | Arthritis | 4 | 2020 | 111 | 1.080 |
Why?
| | Monocytes | 3 | 2020 | 504 | 1.080 |
Why?
| | Arginase | 3 | 2015 | 27 | 1.070 |
Why?
| | Viremia | 3 | 2023 | 122 | 1.050 |
Why?
| | B-Lymphocytes | 4 | 2020 | 771 | 1.010 |
Why?
| | Antibodies, Neutralizing | 9 | 2023 | 223 | 0.980 |
Why?
| | Joints | 4 | 2020 | 84 | 0.930 |
Why?
| | Immunity, Innate | 7 | 2022 | 735 | 0.910 |
Why?
| | Interferon Regulatory Factors | 2 | 2022 | 30 | 0.890 |
Why?
| | RNA Virus Infections | 3 | 2019 | 11 | 0.880 |
Why?
| | Kupffer Cells | 2 | 2021 | 45 | 0.870 |
Why?
| | Virulence | 10 | 2021 | 231 | 0.870 |
Why?
| | Virion | 3 | 2022 | 74 | 0.870 |
Why?
| | Musculoskeletal Diseases | 2 | 2016 | 55 | 0.860 |
Why?
| | Inflammation | 9 | 2023 | 2502 | 0.820 |
Why?
| | Macrophages | 6 | 2022 | 1282 | 0.820 |
Why?
| | Adaptor Proteins, Signal Transducing | 5 | 2021 | 377 | 0.810 |
Why?
| | Mice, Knockout | 17 | 2022 | 2609 | 0.810 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2021 | 688 | 0.770 |
Why?
| | Neutrophils | 2 | 2020 | 1171 | 0.760 |
Why?
| | Myeloid Differentiation Factor 88 | 2 | 2020 | 90 | 0.750 |
Why?
| | Viral Fusion Proteins | 8 | 2001 | 20 | 0.740 |
Why?
| | Capsid Proteins | 3 | 2020 | 69 | 0.730 |
Why?
| | RNA Viruses | 2 | 2019 | 28 | 0.730 |
Why?
| | Myositis | 3 | 2012 | 43 | 0.720 |
Why?
| | RNA, Viral | 13 | 2021 | 564 | 0.710 |
Why?
| | Viral Nonstructural Proteins | 3 | 2021 | 56 | 0.710 |
Why?
| | Quinolones | 1 | 2021 | 97 | 0.710 |
Why?
| | Complement System Proteins | 4 | 2023 | 288 | 0.700 |
Why?
| | NADPH Oxidase 2 | 1 | 2020 | 42 | 0.700 |
Why?
| | O'nyong-nyong Virus | 1 | 2019 | 4 | 0.700 |
Why?
| | Herpesvirus 4, Human | 4 | 2004 | 123 | 0.690 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2020 | 160 | 0.680 |
Why?
| | Dendritic Cells | 2 | 2021 | 438 | 0.660 |
Why?
| | Leishmania major | 1 | 2018 | 6 | 0.650 |
Why?
| | Leishmaniasis, Cutaneous | 1 | 2018 | 7 | 0.650 |
Why?
| | Myeloid Cells | 3 | 2015 | 127 | 0.640 |
Why?
| | Muscle, Skeletal | 9 | 2020 | 1459 | 0.620 |
Why?
| | Trans-Activators | 4 | 2004 | 369 | 0.610 |
Why?
| | Osteoarthritis | 1 | 2020 | 173 | 0.600 |
Why?
| | Pathogen-Associated Molecular Pattern Molecules | 1 | 2017 | 6 | 0.580 |
Why?
| | Chronic Disease | 4 | 2019 | 1598 | 0.560 |
Why?
| | Superoxide Dismutase | 1 | 2018 | 332 | 0.550 |
Why?
| | Mutation, Missense | 2 | 2019 | 297 | 0.550 |
Why?
| | Disease Outbreaks | 4 | 2023 | 308 | 0.550 |
Why?
| | Zika Virus | 1 | 2017 | 61 | 0.550 |
Why?
| | Gene Deletion | 3 | 2018 | 356 | 0.550 |
Why?
| | Amino Acid Substitution | 3 | 2014 | 267 | 0.540 |
Why?
| | Zika Virus Infection | 1 | 2017 | 85 | 0.520 |
Why?
| | Immunization | 4 | 2024 | 402 | 0.510 |
Why?
| | Cell Line | 18 | 2021 | 2657 | 0.500 |
Why?
| | Complement Activation | 5 | 2018 | 343 | 0.490 |
Why?
| | Humans | 63 | 2023 | 115879 | 0.480 |
Why?
| | Tyrosine | 3 | 2013 | 218 | 0.440 |
Why?
| | Endothelial Cells | 4 | 2024 | 695 | 0.440 |
Why?
| | Arthralgia | 1 | 2013 | 50 | 0.430 |
Why?
| | Membrane Fusion | 3 | 2001 | 40 | 0.430 |
Why?
| | Histidine | 1 | 2013 | 57 | 0.430 |
Why?
| | Immunity, Cellular | 1 | 2014 | 263 | 0.430 |
Why?
| | DNA-Binding Proteins | 3 | 2004 | 1318 | 0.410 |
Why?
| | Sindbis Virus | 4 | 2017 | 9 | 0.400 |
Why?
| | Severe Acute Respiratory Syndrome | 4 | 2018 | 14 | 0.400 |
Why?
| | Antibodies, Monoclonal | 4 | 2020 | 1264 | 0.380 |
Why?
| | Tenosynovitis | 1 | 2010 | 12 | 0.380 |
Why?
| | Emergency Responders | 2 | 2021 | 33 | 0.370 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2021 | 171 | 0.340 |
Why?
| | Vero Cells | 9 | 2021 | 65 | 0.340 |
Why?
| | Mice, Transgenic | 4 | 2021 | 1971 | 0.340 |
Why?
| | Up-Regulation | 1 | 2012 | 824 | 0.330 |
Why?
| | T-Lymphocytes | 2 | 2019 | 1758 | 0.330 |
Why?
| | HN Protein | 3 | 1993 | 5 | 0.320 |
Why?
| | Lymphoid Tissue | 2 | 2019 | 63 | 0.320 |
Why?
| | Macrophage-1 Antigen | 1 | 2008 | 33 | 0.320 |
Why?
| | Virus Diseases | 1 | 2011 | 200 | 0.320 |
Why?
| | Spike Glycoprotein, Coronavirus | 4 | 2022 | 94 | 0.310 |
Why?
| | Arboviruses | 1 | 2008 | 10 | 0.310 |
Why?
| | Phenylalanine | 2 | 2022 | 58 | 0.310 |
Why?
| | Signal Transduction | 9 | 2021 | 4528 | 0.310 |
Why?
| | Cell Membrane | 4 | 2018 | 683 | 0.300 |
Why?
| | Arbovirus Infections | 1 | 2008 | 17 | 0.300 |
Why?
| | Cricetinae | 6 | 2020 | 260 | 0.300 |
Why?
| | Complement C3 | 4 | 2018 | 191 | 0.300 |
Why?
| | Adoptive Transfer | 2 | 2020 | 200 | 0.300 |
Why?
| | Adenoviridae | 2 | 2021 | 186 | 0.290 |
Why?
| | Mutagenesis, Site-Directed | 7 | 2010 | 346 | 0.290 |
Why?
| | Epitopes | 2 | 2020 | 438 | 0.290 |
Why?
| | Phosphoproteins | 3 | 2016 | 302 | 0.270 |
Why?
| | West Nile virus | 2 | 2016 | 38 | 0.270 |
Why?
| | Arthritis, Infectious | 1 | 2006 | 50 | 0.250 |
Why?
| | Cytokines | 5 | 2020 | 1858 | 0.250 |
Why?
| | Mice, Inbred BALB C | 4 | 2018 | 1169 | 0.250 |
Why?
| | Down-Regulation | 2 | 2004 | 605 | 0.240 |
Why?
| | Macaca mulatta | 2 | 2023 | 132 | 0.240 |
Why?
| | Immunoglobulin G | 4 | 2022 | 782 | 0.240 |
Why?
| | Immunoassay | 2 | 2021 | 97 | 0.230 |
Why?
| | Membrane Proteins | 2 | 2022 | 1033 | 0.230 |
Why?
| | Genome, Viral | 4 | 2019 | 121 | 0.230 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2023 | 25 | 0.230 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2004 | 140 | 0.220 |
Why?
| | Lymphocyte Activation | 2 | 2018 | 1056 | 0.220 |
Why?
| | Killer Cells, Natural | 3 | 2019 | 382 | 0.210 |
Why?
| | Robotics | 1 | 2023 | 79 | 0.210 |
Why?
| | Antigens, Viral | 2 | 2021 | 177 | 0.210 |
Why?
| | Arthritis, Rheumatoid | 1 | 2010 | 1003 | 0.210 |
Why?
| | Robotic Surgical Procedures | 1 | 2023 | 88 | 0.200 |
Why?
| | Salmonella | 1 | 2022 | 54 | 0.200 |
Why?
| | Protein Biosynthesis | 4 | 2019 | 390 | 0.200 |
Why?
| | NF-kappa B | 2 | 2008 | 639 | 0.200 |
Why?
| | Transcriptional Activation | 2 | 2022 | 341 | 0.200 |
Why?
| | Vaccines, Attenuated | 1 | 2022 | 113 | 0.200 |
Why?
| | Base Sequence | 9 | 2010 | 2121 | 0.190 |
Why?
| | Benzene Derivatives | 1 | 2021 | 9 | 0.190 |
Why?
| | Oligosaccharides | 1 | 2001 | 47 | 0.190 |
Why?
| | Mice, Mutant Strains | 1 | 2021 | 271 | 0.190 |
Why?
| | Horses | 1 | 2021 | 97 | 0.190 |
Why?
| | Cell Proliferation | 2 | 2018 | 2196 | 0.190 |
Why?
| | Convalescence | 1 | 2021 | 15 | 0.190 |
Why?
| | Interferon-gamma | 3 | 2010 | 733 | 0.190 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2004 | 394 | 0.190 |
Why?
| | Protein Domains | 1 | 2022 | 209 | 0.190 |
Why?
| | Gynecology | 1 | 2023 | 185 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2001 | 71 | 0.180 |
Why?
| | Specimen Handling | 1 | 2022 | 157 | 0.180 |
Why?
| | Oocytes | 2 | 2004 | 172 | 0.180 |
Why?
| | Influenza, Human | 2 | 2020 | 548 | 0.180 |
Why?
| | Receptors, Mitogen | 1 | 2020 | 8 | 0.180 |
Why?
| | Culicidae | 2 | 2013 | 29 | 0.180 |
Why?
| | Lectins, C-Type | 1 | 2020 | 62 | 0.180 |
Why?
| | Type C Phospholipases | 1 | 2000 | 66 | 0.180 |
Why?
| | Xenopus | 1 | 2000 | 99 | 0.180 |
Why?
| | Single-Cell Analysis | 1 | 2021 | 181 | 0.180 |
Why?
| | Interferon Regulatory Factor-3 | 2 | 2017 | 17 | 0.180 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2022 | 284 | 0.180 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2019 | 17 | 0.170 |
Why?
| | Glycoproteins | 2 | 2016 | 311 | 0.170 |
Why?
| | Blood Donors | 1 | 2021 | 89 | 0.170 |
Why?
| | Mutation | 5 | 2021 | 3371 | 0.170 |
Why?
| | Encephalomyelitis, Venezuelan Equine | 1 | 2019 | 1 | 0.170 |
Why?
| | STAT1 Transcription Factor | 2 | 2010 | 62 | 0.170 |
Why?
| | Benzylamines | 1 | 2019 | 39 | 0.170 |
Why?
| | Laparoscopy | 1 | 2023 | 400 | 0.170 |
Why?
| | RNA, Double-Stranded | 1 | 2019 | 44 | 0.170 |
Why?
| | Blotting, Western | 3 | 2015 | 1153 | 0.170 |
Why?
| | Homeodomain Proteins | 3 | 2014 | 465 | 0.170 |
Why?
| | Primates | 2 | 2017 | 111 | 0.170 |
Why?
| | Molecular Sequence Data | 7 | 2010 | 2796 | 0.170 |
Why?
| | Leishmania donovani | 1 | 2018 | 3 | 0.160 |
Why?
| | Parasite Load | 1 | 2018 | 8 | 0.160 |
Why?
| | Viral Tropism | 2 | 2019 | 24 | 0.160 |
Why?
| | Progesterone | 1 | 2000 | 232 | 0.160 |
Why?
| | Lung | 5 | 2023 | 3683 | 0.160 |
Why?
| | Venules | 1 | 2018 | 13 | 0.160 |
Why?
| | Chemokine CCL21 | 1 | 2018 | 13 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1138 | 0.160 |
Why?
| | Endothelium, Lymphatic | 1 | 2018 | 12 | 0.160 |
Why?
| | src-Family Kinases | 1 | 2019 | 87 | 0.160 |
Why?
| | Genes, Viral | 5 | 2006 | 89 | 0.160 |
Why?
| | Female | 17 | 2021 | 60082 | 0.160 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2019 | 967 | 0.160 |
Why?
| | RNA, Messenger | 3 | 2019 | 2581 | 0.150 |
Why?
| | Interferon Regulatory Factor-7 | 1 | 2017 | 4 | 0.150 |
Why?
| | Ovalbumin | 1 | 2018 | 166 | 0.150 |
Why?
| | Stromal Cells | 1 | 2018 | 97 | 0.150 |
Why?
| | Heparin-binding EGF-like Growth Factor | 1 | 2017 | 11 | 0.150 |
Why?
| | Aedes | 2 | 2019 | 55 | 0.150 |
Why?
| | Hindlimb | 2 | 2010 | 125 | 0.150 |
Why?
| | Antigens, Ly | 1 | 2017 | 45 | 0.150 |
Why?
| | Receptors, CCR2 | 1 | 2017 | 28 | 0.150 |
Why?
| | Methotrexate | 1 | 2019 | 228 | 0.150 |
Why?
| | Diphtheria Toxin | 1 | 2017 | 51 | 0.150 |
Why?
| | Lysine | 1 | 2019 | 246 | 0.150 |
Why?
| | Gene Expression | 4 | 2015 | 1442 | 0.150 |
Why?
| | Protein Processing, Post-Translational | 4 | 2012 | 401 | 0.150 |
Why?
| | Polysaccharides | 1 | 2018 | 80 | 0.150 |
Why?
| | Transfection | 6 | 2009 | 868 | 0.140 |
Why?
| | HeLa Cells | 5 | 2023 | 567 | 0.140 |
Why?
| | Mutant Proteins | 2 | 2014 | 96 | 0.140 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 138 | 0.140 |
Why?
| | Mannose-Binding Lectin | 2 | 2018 | 21 | 0.140 |
Why?
| | Toll-Like Receptors | 1 | 2017 | 166 | 0.140 |
Why?
| | Bacterial Proteins | 1 | 2022 | 740 | 0.140 |
Why?
| | Antirheumatic Agents | 1 | 2019 | 255 | 0.140 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 446 | 0.140 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2016 | 45 | 0.130 |
Why?
| | Cytoplasm | 2 | 2017 | 255 | 0.130 |
Why?
| | Oxidative Stress | 1 | 2022 | 1095 | 0.130 |
Why?
| | alpha-Synuclein | 1 | 2015 | 21 | 0.130 |
Why?
| | Schistosomiasis mansoni | 1 | 2015 | 24 | 0.130 |
Why?
| | Male | 11 | 2021 | 56117 | 0.130 |
Why?
| | Schistosoma mansoni | 1 | 2015 | 39 | 0.130 |
Why?
| | RNA Caps | 1 | 2015 | 31 | 0.130 |
Why?
| | Epidemiological Monitoring | 1 | 2015 | 47 | 0.120 |
Why?
| | Histocompatibility Antigen H-2D | 1 | 2014 | 21 | 0.120 |
Why?
| | Vaccination | 2 | 2021 | 1210 | 0.120 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2015 | 35 | 0.120 |
Why?
| | Communicable Disease Control | 1 | 2015 | 66 | 0.120 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2015 | 112 | 0.120 |
Why?
| | Friend murine leukemia virus | 1 | 2015 | 30 | 0.120 |
Why?
| | Cytidine Deaminase | 1 | 2015 | 57 | 0.120 |
Why?
| | Mannose-Binding Protein-Associated Serine Proteases | 1 | 2014 | 22 | 0.120 |
Why?
| | Flow Cytometry | 2 | 2015 | 1060 | 0.120 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2014 | 26 | 0.120 |
Why?
| | Animal Structures | 1 | 2014 | 8 | 0.120 |
Why?
| | Gene Expression Regulation, Viral | 2 | 2012 | 80 | 0.110 |
Why?
| | Hospitalization | 1 | 2022 | 1766 | 0.110 |
Why?
| | Glycosaminoglycans | 1 | 2013 | 80 | 0.110 |
Why?
| | Pandemics | 3 | 2023 | 1339 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 789 | 0.110 |
Why?
| | Fibroblasts | 1 | 2018 | 839 | 0.110 |
Why?
| | ELAV Proteins | 1 | 2012 | 17 | 0.110 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 378 | 0.110 |
Why?
| | Amino Acids | 1 | 2016 | 456 | 0.110 |
Why?
| | Arthritis, Experimental | 1 | 2014 | 133 | 0.110 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 1001 | 0.110 |
Why?
| | Mycobacterium tuberculosis | 1 | 2015 | 271 | 0.110 |
Why?
| | Amino Acid Sequence | 6 | 1994 | 2003 | 0.100 |
Why?
| | Carrier Proteins | 1 | 2016 | 703 | 0.100 |
Why?
| | Arthritis, Reactive | 1 | 2012 | 8 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 1842 | 0.100 |
Why?
| | Structure-Activity Relationship | 3 | 2021 | 511 | 0.100 |
Why?
| | Synovial Fluid | 2 | 2012 | 57 | 0.100 |
Why?
| | Influenza A Virus, H5N1 Subtype | 1 | 2011 | 5 | 0.100 |
Why?
| | Newcastle Disease | 1 | 1990 | 1 | 0.090 |
Why?
| | Avian Leukosis Virus | 1 | 1990 | 6 | 0.090 |
Why?
| | Transcription, Genetic | 3 | 2004 | 1317 | 0.090 |
Why?
| | Reassortant Viruses | 1 | 2010 | 7 | 0.090 |
Why?
| | Protective Agents | 1 | 2011 | 38 | 0.090 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 141 | 0.090 |
Why?
| | Chickens | 1 | 1990 | 183 | 0.090 |
Why?
| | DNA, Viral | 5 | 1993 | 351 | 0.090 |
Why?
| | Immunotherapy | 1 | 2014 | 481 | 0.090 |
Why?
| | Receptors, Interferon | 1 | 2010 | 49 | 0.090 |
Why?
| | Genetic Vectors | 3 | 2021 | 298 | 0.090 |
Why?
| | COS Cells | 2 | 2001 | 175 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 139 | 0.080 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2009 | 15 | 0.080 |
Why?
| | CCAAT-Enhancer-Binding Protein-beta | 1 | 2009 | 32 | 0.080 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 73 | 0.080 |
Why?
| | Time Factors | 2 | 2021 | 6182 | 0.080 |
Why?
| | Calgranulin B | 1 | 2008 | 6 | 0.080 |
Why?
| | Flavivirus Infections | 1 | 2008 | 9 | 0.080 |
Why?
| | Flavivirus | 1 | 2008 | 16 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 796 | 0.070 |
Why?
| | Cricetulus | 3 | 2014 | 99 | 0.070 |
Why?
| | Small Molecule Libraries | 2 | 2019 | 81 | 0.070 |
Why?
| | Promoter Regions, Genetic | 2 | 2009 | 1130 | 0.070 |
Why?
| | Histocytochemistry | 1 | 2007 | 78 | 0.070 |
Why?
| | Insect Vectors | 1 | 2006 | 27 | 0.070 |
Why?
| | Serum | 1 | 2007 | 57 | 0.070 |
Why?
| | Cell Survival | 2 | 2021 | 1024 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2004 | 0.070 |
Why?
| | Mitochondrial Proteins | 1 | 2008 | 219 | 0.070 |
Why?
| | Glycosylation | 2 | 2006 | 133 | 0.060 |
Why?
| | Organ Specificity | 1 | 2006 | 274 | 0.060 |
Why?
| | Phosphorylation | 4 | 2012 | 1562 | 0.060 |
Why?
| | Enzyme Inhibitors | 2 | 2016 | 758 | 0.060 |
Why?
| | Chick Embryo | 4 | 1992 | 122 | 0.060 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2004 | 52 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2008 | 677 | 0.060 |
Why?
| | Genes, Immediate-Early | 1 | 2004 | 18 | 0.060 |
Why?
| | I-kappa B Proteins | 1 | 2004 | 78 | 0.060 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2004 | 111 | 0.060 |
Why?
| | Plasmids | 3 | 1991 | 346 | 0.060 |
Why?
| | Transcription Factor RelA | 1 | 2004 | 83 | 0.060 |
Why?
| | Brain | 1 | 2015 | 2372 | 0.060 |
Why?
| | HEK293 Cells | 2 | 2019 | 603 | 0.060 |
Why?
| | CHO Cells | 2 | 2014 | 140 | 0.060 |
Why?
| | Immediate-Early Proteins | 1 | 2004 | 53 | 0.060 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2004 | 155 | 0.060 |
Why?
| | Cell Line, Transformed | 1 | 2004 | 133 | 0.060 |
Why?
| | Centrifugation, Density Gradient | 2 | 2001 | 41 | 0.060 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2023 | 53 | 0.060 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 147 | 0.060 |
Why?
| | Culture Media, Conditioned | 1 | 2023 | 105 | 0.050 |
Why?
| | Cloning, Molecular | 3 | 2008 | 523 | 0.050 |
Why?
| | Binding Sites | 2 | 2021 | 1182 | 0.050 |
Why?
| | Coculture Techniques | 1 | 2023 | 204 | 0.050 |
Why?
| | Bone and Bones | 1 | 2006 | 283 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 2 | 2009 | 617 | 0.050 |
Why?
| | Body Weight | 1 | 2007 | 868 | 0.050 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2023 | 154 | 0.050 |
Why?
| | Keratinocytes | 1 | 2004 | 218 | 0.050 |
Why?
| | Mitochondria | 1 | 2008 | 750 | 0.050 |
Why?
| | Immunity, Humoral | 1 | 2023 | 112 | 0.050 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2022 | 52 | 0.050 |
Why?
| | Basal Ganglia Diseases | 1 | 2001 | 8 | 0.050 |
Why?
| | Survival Analysis | 2 | 2015 | 1218 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2004 | 554 | 0.050 |
Why?
| | Australia | 1 | 2022 | 207 | 0.050 |
Why?
| | Central Nervous System Vascular Malformations | 1 | 2001 | 23 | 0.050 |
Why?
| | Cross Protection | 1 | 2021 | 4 | 0.050 |
Why?
| | World Health Organization | 1 | 2022 | 106 | 0.050 |
Why?
| | Colorado | 2 | 2021 | 4122 | 0.050 |
Why?
| | Cross Reactions | 1 | 2021 | 117 | 0.050 |
Why?
| | Oxidoreductases Acting on CH-CH Group Donors | 1 | 2021 | 20 | 0.050 |
Why?
| | Microsomes, Liver | 1 | 2021 | 57 | 0.050 |
Why?
| | Half-Life | 1 | 2021 | 145 | 0.050 |
Why?
| | Microspheres | 1 | 2021 | 123 | 0.050 |
Why?
| | Immunity | 1 | 2001 | 125 | 0.050 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 102 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2008 | 2590 | 0.050 |
Why?
| | Metformin | 1 | 2004 | 278 | 0.050 |
Why?
| | Tyrphostins | 1 | 2000 | 14 | 0.050 |
Why?
| | Phosphotyrosine | 1 | 2000 | 33 | 0.050 |
Why?
| | Giant Cells | 2 | 1998 | 21 | 0.050 |
Why?
| | Genetic Engineering | 1 | 2021 | 81 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2022 | 251 | 0.050 |
Why?
| | Phosphoserine | 1 | 2000 | 33 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 1 | 2001 | 399 | 0.040 |
Why?
| | Interleukin-1 | 1 | 2004 | 971 | 0.040 |
Why?
| | Kinetics | 2 | 2013 | 1568 | 0.040 |
Why?
| | Cells, Cultured | 3 | 2015 | 3914 | 0.040 |
Why?
| | GTP-Binding Proteins | 1 | 2000 | 142 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 550 | 0.040 |
Why?
| | NIH 3T3 Cells | 1 | 2019 | 138 | 0.040 |
Why?
| | Mosquito Vectors | 1 | 2019 | 21 | 0.040 |
Why?
| | Protein Transport | 2 | 2012 | 400 | 0.040 |
Why?
| | Poly I-C | 1 | 2018 | 52 | 0.040 |
Why?
| | Interferon-beta | 2 | 2009 | 80 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2000 | 792 | 0.040 |
Why?
| | Trypsin | 1 | 1998 | 67 | 0.040 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2018 | 22 | 0.040 |
Why?
| | Autocrine Communication | 1 | 2018 | 43 | 0.040 |
Why?
| | Molecular Structure | 1 | 2019 | 447 | 0.040 |
Why?
| | Spleen | 1 | 2019 | 492 | 0.040 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 124 | 0.040 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2018 | 45 | 0.040 |
Why?
| | Length of Stay | 1 | 2022 | 960 | 0.040 |
Why?
| | Paracrine Communication | 1 | 2018 | 56 | 0.040 |
Why?
| | Chemokines | 1 | 2018 | 214 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2019 | 332 | 0.040 |
Why?
| | Eukaryotic Initiation Factors | 1 | 2016 | 9 | 0.040 |
Why?
| | Capsid | 1 | 2017 | 76 | 0.040 |
Why?
| | Biological Transport | 3 | 1992 | 375 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2021 | 1725 | 0.040 |
Why?
| | Virus Assembly | 1 | 2017 | 67 | 0.040 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2016 | 37 | 0.030 |
Why?
| | Ouabain | 1 | 2016 | 15 | 0.030 |
Why?
| | Digoxin | 1 | 2016 | 26 | 0.030 |
Why?
| | RNA, Small Interfering | 2 | 2009 | 545 | 0.030 |
Why?
| | Transcription Factors | 1 | 2004 | 1535 | 0.030 |
Why?
| | Carbonyl Cyanide m-Chlorophenyl Hydrazone | 2 | 1985 | 4 | 0.030 |
Why?
| | Monensin | 2 | 1985 | 6 | 0.030 |
Why?
| | Drug Resistance, Viral | 1 | 2016 | 99 | 0.030 |
Why?
| | Granuloma | 1 | 2015 | 85 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 1871 | 0.030 |
Why?
| | Viral Plaque Assay | 2 | 1992 | 24 | 0.030 |
Why?
| | Apoptosis | 1 | 2004 | 2377 | 0.030 |
Why?
| | International Cooperation | 1 | 2015 | 175 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 944 | 0.030 |
Why?
| | Calcium | 1 | 2000 | 1103 | 0.030 |
Why?
| | RNA Stability | 1 | 2015 | 93 | 0.030 |
Why?
| | Vesicular stomatitis Indiana virus | 1 | 1974 | 13 | 0.030 |
Why?
| | Reticulocytes | 1 | 1974 | 17 | 0.030 |
Why?
| | Virus Attachment | 1 | 2013 | 11 | 0.030 |
Why?
| | Transduction, Genetic | 1 | 2014 | 121 | 0.030 |
Why?
| | Heparitin Sulfate | 1 | 2013 | 42 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2807 | 0.030 |
Why?
| | Virus Internalization | 1 | 2013 | 41 | 0.030 |
Why?
| | Precipitin Tests | 1 | 1993 | 90 | 0.030 |
Why?
| | Static Electricity | 1 | 2013 | 117 | 0.030 |
Why?
| | Hydrogen Bonding | 1 | 2013 | 145 | 0.030 |
Why?
| | Cell Fusion | 1 | 1993 | 50 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2020 | 2750 | 0.030 |
Why?
| | Conserved Sequence | 1 | 1993 | 220 | 0.030 |
Why?
| | Protein Binding | 2 | 2009 | 1918 | 0.030 |
Why?
| | Global Health | 1 | 2015 | 290 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2014 | 187 | 0.030 |
Why?
| | Endosomes | 1 | 2013 | 125 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 555 | 0.030 |
Why?
| | Oligodeoxyribonucleotides | 1 | 1993 | 138 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2013 | 160 | 0.030 |
Why?
| | Proteolysis | 1 | 2012 | 145 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 137 | 0.020 |
Why?
| | Caspases | 1 | 2012 | 245 | 0.020 |
Why?
| | Viral Structural Proteins | 1 | 1991 | 12 | 0.020 |
Why?
| | Poultry | 1 | 1990 | 9 | 0.020 |
Why?
| | Complement C5a | 1 | 2011 | 59 | 0.020 |
Why?
| | Orthomyxoviridae | 1 | 1991 | 35 | 0.020 |
Why?
| | Tritium | 2 | 1985 | 69 | 0.020 |
Why?
| | Orthomyxoviridae Infections | 1 | 2011 | 55 | 0.020 |
Why?
| | Insulin | 1 | 2000 | 2084 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 1985 | 313 | 0.020 |
Why?
| | DNA | 2 | 1988 | 1357 | 0.020 |
Why?
| | Middle Aged | 2 | 2021 | 27085 | 0.020 |
Why?
| | Vaccines, Synthetic | 1 | 1990 | 124 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2001 | 3072 | 0.020 |
Why?
| | Polyribosomes | 2 | 1984 | 23 | 0.020 |
Why?
| | Chloramphenicol O-Acetyltransferase | 1 | 2009 | 38 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2010 | 298 | 0.020 |
Why?
| | Antibody Formation | 1 | 1990 | 274 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2009 | 74 | 0.020 |
Why?
| | Receptors, CCR | 1 | 2008 | 7 | 0.020 |
Why?
| | Virus Cultivation | 1 | 2008 | 25 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2009 | 132 | 0.020 |
Why?
| | Models, Molecular | 1 | 2013 | 1391 | 0.020 |
Why?
| | Immunoblotting | 1 | 2009 | 283 | 0.020 |
Why?
| | Seasons | 1 | 2011 | 450 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1830 | 0.020 |
Why?
| | Oligonucleotides | 1 | 2009 | 138 | 0.020 |
Why?
| | Neurons | 1 | 2015 | 1298 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 390 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 935 | 0.020 |
Why?
| | Genes | 1 | 1988 | 224 | 0.020 |
Why?
| | Mitochondrial Membranes | 1 | 2008 | 32 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 8715 | 0.020 |
Why?
| | Protein Conformation | 2 | 1992 | 822 | 0.020 |
Why?
| | DNA, Recombinant | 1 | 1986 | 42 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 1986 | 189 | 0.020 |
Why?
| | Mercaptoethanol | 1 | 1985 | 11 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2006 | 117 | 0.020 |
Why?
| | Fucose | 1 | 1985 | 3 | 0.020 |
Why?
| | Disulfides | 1 | 1985 | 91 | 0.020 |
Why?
| | Immune System | 1 | 2006 | 173 | 0.010 |
Why?
| | Poly A | 1 | 1984 | 46 | 0.010 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2004 | 44 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2004 | 47 | 0.010 |
Why?
| | Receptor, Insulin | 1 | 2004 | 93 | 0.010 |
Why?
| | Computational Biology | 1 | 2008 | 540 | 0.010 |
Why?
| | Xenopus laevis | 1 | 2004 | 118 | 0.010 |
Why?
| | Response Elements | 1 | 2004 | 83 | 0.010 |
Why?
| | RNA | 1 | 2010 | 820 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2010 | 1551 | 0.010 |
Why?
| | Models, Genetic | 1 | 2006 | 579 | 0.010 |
Why?
| | Adult | 2 | 2021 | 30822 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2004 | 804 | 0.010 |
Why?
| | Basal Ganglia | 1 | 2001 | 42 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1244 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2009 | 2365 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2004 | 1008 | 0.010 |
Why?
| | Carcinoma, Krebs 2 | 1 | 1974 | 1 | 0.010 |
Why?
| | Electrophoresis, Paper | 1 | 1974 | 1 | 0.010 |
Why?
| | Chromatography, Paper | 1 | 1974 | 3 | 0.010 |
Why?
| | Sulfur Radioisotopes | 1 | 1974 | 17 | 0.010 |
Why?
| | Hydroxyapatites | 1 | 1974 | 13 | 0.010 |
Why?
| | Chromatography | 1 | 1974 | 24 | 0.010 |
Why?
| | Peptide Biosynthesis | 1 | 1974 | 13 | 0.010 |
Why?
| | Carbon Radioisotopes | 1 | 1974 | 38 | 0.010 |
Why?
| | Tissue Extracts | 1 | 1974 | 20 | 0.010 |
Why?
| | Autoradiography | 1 | 1974 | 71 | 0.010 |
Why?
| | Cell-Free System | 1 | 1974 | 47 | 0.010 |
Why?
| | Triticum | 1 | 1974 | 10 | 0.010 |
Why?
| | Peptide Chain Initiation, Translational | 1 | 1974 | 38 | 0.010 |
Why?
| | Genetic Complementation Test | 1 | 1992 | 61 | 0.010 |
Why?
| | Viral Matrix Proteins | 1 | 1992 | 24 | 0.010 |
Why?
| | Rabbits | 1 | 1974 | 754 | 0.010 |
Why?
| | Sequence Alignment | 1 | 1992 | 328 | 0.010 |
Why?
|
|
Morrison's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|